SQZ Biotech recently announced a cancer-fighting partnership with pharmaceutical firm Roche. Headed by Koch Institute visiting scientist and former postdoc Armon Sharei, SQZ also counts several Koch Institute members among its Boards of Directors (Robert Langer) and Scientific Advisors (Tyler Jacks, Darrell Irvine, and Christopher Love). SQZ uses a device invented by Sharei, called CellSqueeze, to engineer cell-based therapies for disease, most notably B cell-driven immunotherapies for a broad range of cancers. Earlier this year, SQZ was named one of FierceBiotech's 2015 Fierce 15, and the CellSqueeze device was named one of Scientific American's top ten world-changing ideas of 2014. Development of SQZ's B cells was initially supported by the Koch Institute Frontier Research Program through the Kathy and Curt Marble Cancer Research Fund.